Filing Flows › Roivant Sciences (ROIV) › Q2 FY27 › vs Q2 FY26
Roivant Sciences (ROIV) Q2 FY27 vs Q2 FY26 (year over year)
Roivant Sciences's revenue rose $33.5M (22×) from $1.6M in Q2 FY26 to $35.1M in Q2 FY27. The biggest changes: Product revenue, net +$31.0M (—); License, milestone and other revenue +$2.6M (+164%).
Roivant Sciences, Q2 FY27: revenue $35.1M (22× year over year), operating margin -763.2%, net loss $137M, operating cash flow $594M. The chart draws each line against Q2 FY26, the increases inside each band.
Every line
| Line | Q2 FY27 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $31.0M | $0 | $31.0M | — |
| License, milestone and other revenue | $4.2M | $1.6M | $2.6M | +164% |
| Revenue | $35.1M | $1.6M | $33.5M | 22× |
| Other income, net | $117M | $147M | −$29.7M | -20% |
| Income tax benefit | $13.4M | −$7.0M | $20.4M | — |
| Net loss | $137M | $166M | −$28.8M | -17% |
| Costs & expenses | $303M | $315M | −$11.6M | -4% |
| Operating costs | $303M | $308M | −$4.6M | -2% |
| Cost of revenue | $3.3M | $111K | $3.2M | 30× |
| Research & development | $146M | $165M | −$18.8M | -11% |
| SG&A | $154M | $143M | $11.0M | +8% |
| Operating cash sources | $732M | −$19.6M | $751M | — |
| Depreciation & amortization | $604K | $921K | −$317K | -34% |
| Share-based compensation | $79.3M | $81.8M | −$2.5M | -3% |
| Working capital & other | $652M | −$102M | $754M | — |
| Net loss absorbed | $137M | $166M | −$28.8M | -17% |
| Operating cash flow | $594M | −$186M | $780M | — |
| Free cash flow (OCF − capex) | $594M | −$194M | $788M | — |
| Capital expenditures | $208K | $7.8M | −$7.6M | -97% |
Questions
How much did Roivant Sciences's revenue grow year over year in Q2 FY27?
Roivant Sciences's revenue rose $33.5M (22×) from $1.6M in Q2 FY26 to $35.1M in Q2 FY27.
What drove Roivant Sciences's revenue change in Q2 FY27?
Product revenue, net +$31.0M (—); License, milestone and other revenue +$2.6M (+164%).